PUXTARROW
"PUXTARROW" is a word mark owned by AstraZeneca AB, filed at the CIPO on August 6, 2026. It is filed and waiting for examination and covers class 5 (Pharmaceuticals).
- Status
- Filed
- Since August 6, 2026
- Filed
- August 6, 2026
- Registered
- Not yet
- Priority date
- April 1, 2026
- Application no.
- 2493085
- Registration no.
- Not yet
- Office
- CIPO
- Canadian Intellectual Property Office
- Mark type
- Word mark
- 1 class
Who owns PUXTARROW
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
AstraZeneca AB
Sweden
Representative
Smart & Biggar LP
Smart & Biggar LP
What the mark covers
The products and services PUXTARROW is filed for, grouped by Nice class.
Pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment of oncologic diseases and disorders; pharmaceutical preparations and substances for use in the treatment of cardiovascular, renal, endocrine, respiratory, inflammatory, immunologic, hematological, gastrointestinal, and autoimmune diseases and disorders; pharmaceutical preparations and substances for use in the treatment of metabolic diseases and disorders, namely, cirrhosis, dyslipidaemia, metabolic dysfunction-associated steatohepatitis, chronic weight management and obesity, primary aldosteronism, transthyretin amyloid cardiomyopathy, amyloidosis with cardiac involvement, mineral metabolism diseases and disorders, metabolic bone diseases and disorders, enzyme function diseases and disorders, and diseases and disorders associated with natural substrates of alkaline phosphatase; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations and substances for use in the treatment of immune-mediated diseases and disorders, namely, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, ANCA associated vasculitis, myositis, B cell mediated autoimmune disease, Crohn's disease, inflammatory vascular diseases, and myeloproliferative disorders; pharmaceutical preparations and substances for use in the treatment of neurological and neurodegenerative diseases and disorders, namely, neuromyelitis optica spectrum disorder (NMOSD), polyneuropathy, neurofibromatosis type 1 with plexiform neurofibromas (NF1 PN), multiple system atrophy (MSA), chronic hypoparathyroidism; pharmaceutical preparations and substances for use in the treatment of infectious diseases and disorders, namely respiratory infections, gastrointestinal infections, skin infections, blood infections; vaccines for human use
What has happened so far
Steps recorded by the CIPO, newest first.
- Formalized
- Created
- Filed
About PUXTARROW
Who owns the trademark "PUXTARROW"?
The CIPO trademark "PUXTARROW" (application 2493085) is owned by AstraZeneca AB.
What is the status of "PUXTARROW"?
Its status at the CIPO is: filed.
Get this data via the API
Everything on this page comes from the Signa API. Pull PUXTARROW and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019ff734-514a-76af-a393-0208a11f10b3
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019ff734-514a-76af-a393-0208a11f10b3",
"object": "trademark",
"mark_text": "PUXTARROW",
"status": {
"primary": "pending",
"stage": "filed"
},
"office_code": "CA",
"application_number": "2493085",
"filing_date": "2026-08-06",
"nice_classes": [
5
],
"owners": [
{
"name": "AstraZeneca AB",
"entity_id": "ent_019f87bc-8390-70e7-98a4-8de9cd32b1f3"
}
]
}